Imperatorin alleviated endometriosis by inhibiting the activation of PI3K/Akt/NF-κB pathway in rats

Tengyun Ma, Panwang Liu, Jiangping Wei, Meihuan Zhao, Xingxing Yao, Xiaohong Luo, Shijun Xu
Life sciences · 2021 · vol. 274 , pp. 119291 · doi:10.1016/j.lfs.2021.119291 · PMID:33667515 · W3135581839
article OA: closed CC0 ⤵ 13 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Imperatorin treatment in rats reduced endometriosis by suppressing the PI3K/Akt/NF-κB signaling pathway.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Furocoumarins Gene Expression Regulation NF-kappa B Phosphatidylinositol 3-Kinases Proto-Oncogene Proteins c-akt Animals Endometriosis Endometriosis Endometriosis Female Furocoumarins Gene Expression Regulation NF-kappa B NF-kappa B Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Rats

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (54)

Cited by (13)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:49.034193+00:00
License: CC0 · commercial use OK